How Can We Effectively Spend Our Health Care Dollars?
(2/18, Going Below the Surface) comments “Health care policy experts gathered for a panel discussion at the AcademyHealth National Health Policy Conference on Feb. 11 to tackle how we can more effectively spend our health care dollars and understand possible tradeoffs. The panel, moderated by National Pharmaceutical Council Chief Science Officer Robert Dubois, featured Stacie Dusetzina, associate professor, Vanderbilt University; Katie Martin, senior fellow, Health Care Cost Institute; Michael Thompson, president and CEO, National Alliance of Healthcare Purchaser Organizations; and Joel White, president, Council for Affordable Health Coverage.” Full
How Important Are the Indirect Benefits of Health Care Innovation?
(2/18, Katie Kuehner-Hebert, Benefits Pro) reports “...Employers also care about whether adopting an innovation within their health care plan would result in reduced absenteeism and caregiver burden, as well as increased presenteeism and quality of life. However, payers place a low priority on such ‘indirect benefits,’ according to new study published in the Journal of Occupational and Environmental Medicine by researchers at the National Pharmaceutical Council and RTI Health Solutions. ‘Several factors may explain this disconnect, including the fact that employers can shift the cost and risk of health care to payers, but they cannot shift broader impacts of lost productivity and functional status outside of their organizational boundaries,’ Michael Ciarametaro, vice president of research at NPC and one of the study's authors, says...” Full
Video: Real-World Data Can Make Up for Clinical Trial Weaknesses, Says Viraj Narayanan
(2/17, The American Journal of Managed Care) “Real-world data can help resolve some challenges commonly faced in clinical trails, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.” View Video
RWE: Cost and Time Savings Entice Sponsors as Pitfalls Linger
(2/14, Zachary Brennan, Regulatory Focus) reports “...The NEJM article, meanwhile, titled ‘The Magic of Randomization versus the Myth of Real-World Evidence,’...notes that ‘because of the potential biases inherent in observational studies, such studies cannot generally be trusted when — as is often the case — the effects of the treatment of interest are actually null or only moderate (i.e., less than a twofold difference in the incidence of the health outcome between using and not using the treatment).’ ‘In those circumstances, large observational studies may yield misleading associations of a treatment with health outcomes that are statistically significant but noncausal, or that are mistakenly null when the treatment really does have clinically important effects,’ they write.” Full
The Role of the Accountable Care Organization in Value-Based Care
(2/17, Emily Sokol, MPH, RevCycle Intelligence) reports “...True value, though, looks different depending on the patient and the ACO...Markets with a diverse payer mix are left to the mercy of their payers to define success. ‘We really don't define value. The payers define what they see as value,’ argued [Coastal Carolina Quality Care, Inc. CEO Stephen Nuckolls]. ‘We move and adhere to the contractual provisions that they give us in these various programs. A payer has some control over what we put on our dashboards because they're the ones paying the bills.’” Full
UK: NICE Recommends New Therapy for Hyperkalaemia
(2/17, Pavankumar Kamat, Medscape) reports “The National Institute for Health and Care Excellence has recommended patiromer (Veltassa, Vifor Fresenius Medical Care Renal Pharma) as a treatment option for hyperkalaemia.” Full
UK: NICE Recommends Wireless Device for Overactive Bladder
(2/14, Anna Smith, PharmaTimes) reports “...Meindert Boysen, director of the centre for health technology evaluation at NICE, said: ‘Clinical trial evidence seen by our independent committee shows that Axonics can help improve quality of life for people with symptoms caused by an overactive bladder. This device will last longer than the current non-rechargeable system, resulting in a cost saving for the NHS after six years of use, and, importantly for patients, fewer replacement surgeries.’” Full
CEADM Applauds CADTH's Decision to Recommend an Innovative Depression Medication for Publicly-Funded Drug Plans in Canada
(2/18, Canadians for Equal Access to Depression Medication Press Release) “...Dr. Sidney Kennedy...responded to CADTH's recent recommendation. ‘Historically, assessing the effectiveness of a depression medication is based on an antiquated approach – “Does this make you feel better?” The 40-percent of people with depression who don't respond to the standard medications need access to a variety of medications. I am hopeful CADTH's recent recommendation that vortioxetine be reimbursed for the treatment of MDD is an acknowledgement that given the 227 combinations of the symptoms of depression, one size of [treatment] does not fit all,’ Dr. Kennedy said.” Full
Out-Of-Network Primary Care Is Associated With Higher Per Beneficiary Spending In Medicare ACOs
Sunny C. Lin, et al.
February 2020, Health Affairs
The Magic of Randomization Versus the Myth of Real-World Evidence
Rory Collins, F.R.S., et al.
February 13, 2020, The New England Journal of Medicine
Does Consumer Engagement in Health Technology Assessment Enhance or Undermine Equity?
Ghinea N, Lipworth W, Kerridge I.
February 14, 2020, Journal of Bioethical Inquiry
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
Chudleigh RA, Platts J, Bain SC
February 18, 2020, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy